Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
NCT ID: NCT06228066
Last Updated: 2025-12-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
45 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-06-13
Study Completion Date
2028-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.
Objective:
To test lurbinectedin with or without avelumab in people with SCCB or HGNET.
Eligibility:
Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment.
Design:
Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor.
Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects.
Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function.
Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.
Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.
Objective:
To test lurbinectedin with or without avelumab in people with SCCB or HGNET.
Eligibility:
Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment.
Design:
Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor.
Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects.
Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function.
Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
NCT03747419
Bladder Cancer
Muscle Invasive Bladder Cancer
TERMINATED
PHASE2
Drug Screening Using IMD in Bladder Cancer
NCT06204614
Muscle Invasive Bladder Urothelial Carcinoma
NOT_YET_RECRUITING
EARLY_PHASE1
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530
Locally Advanced or Metastatic Urothelial Carcinoma
ACTIVE_NOT_RECRUITING
PHASE2
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
NCT04701918
Metastatic Urothelial Carcinoma
Bladder Cancer
COMPLETED
PHASE2
A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine
NCT02101931
Transitional Cell Carcinoma of the Bladder
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
* Small cell carcinoma of the bladder (SCCB) is a rare, aggressive form of bladder cancer, accounting for less than 1% of all bladder malignancies.
* High grade neuroendocrine tumors (HGNET) of the urinary tract are very rare and include both small cell neuroendocrine carcinomas (SCNEC) and large cell neuroendocrine carcinomas (LCNEC).
* Traditionally regimens drawn from the small cell lung cancer literature (cisplatin and etoposide) are used in the frontline setting, and while initially highly responsive to chemotherapy, responses are generally short lived.
* There is little evidence to guide therapeutic decisions at time of disease progression.
* Lurbinectedin is a selective inhibitor of oncogenic transcription that binds preferentially to guanines located in the GC-rich regulatory areas of DNA gene promoters.
* Lurbinectedin prevents binding of transcription factors to their recognition sequences, inhibiting oncogenic transcription and leading to tumor cell apoptosis.
* Lurbinectedin was recently approved as a second line agent in small cell lung cancer, where it has shown an overall response rate of 35%.
* Immune checkpoint inhibitors (ICIs) have become part of the standard of care for small cell lung cancer, and their use in the community for treatment of SCCB has increased.
* However, ICI use in SCCB is still case reportable in the literature, and no prospective studies have been published to date.
Objective:
-To assess the objective response rate (ORR) of lurbinectedin, either alone or in combination with avelumab, in participants with small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract
Eligibility:
* Age \>= 18 years
* Histologically confirmed diagnosis of metastatic SCCB or HGNET of the urinary tract
* Participants must have metastatic disease defined as new or progressive lesions.
* Participants must have at least one measurable site of disease
* Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or HGNET of the urinary tract.
Design:
* This is a Phase II, multisite, open label, nonrandomized study with two cohorts.
* All participants will receive lurbinectedin.
* Participants without prior ICI exposure will be eligible to receive concurrent avelumab.
* Treatment will be given in 21-day cycles continuously for up to 10 years or until signs of progression or intolerable side effects.
* Lurbinectedin will be administered intravenously (I.V.) at 3.2mg/m\^2 every 21 days.
* Avelumab will be administered I.V. at 800mg every 21 days.
* The accrual ceiling will be set at 35 to allow for a small number of inevaluable participants.
* Small cell carcinoma of the bladder (SCCB) is a rare, aggressive form of bladder cancer, accounting for less than 1% of all bladder malignancies.
* High grade neuroendocrine tumors (HGNET) of the urinary tract are very rare and include both small cell neuroendocrine carcinomas (SCNEC) and large cell neuroendocrine carcinomas (LCNEC).
* Traditionally regimens drawn from the small cell lung cancer literature (cisplatin and etoposide) are used in the frontline setting, and while initially highly responsive to chemotherapy, responses are generally short lived.
* There is little evidence to guide therapeutic decisions at time of disease progression.
* Lurbinectedin is a selective inhibitor of oncogenic transcription that binds preferentially to guanines located in the GC-rich regulatory areas of DNA gene promoters.
* Lurbinectedin prevents binding of transcription factors to their recognition sequences, inhibiting oncogenic transcription and leading to tumor cell apoptosis.
* Lurbinectedin was recently approved as a second line agent in small cell lung cancer, where it has shown an overall response rate of 35%.
* Immune checkpoint inhibitors (ICIs) have become part of the standard of care for small cell lung cancer, and their use in the community for treatment of SCCB has increased.
* However, ICI use in SCCB is still case reportable in the literature, and no prospective studies have been published to date.
Objective:
-To assess the objective response rate (ORR) of lurbinectedin, either alone or in combination with avelumab, in participants with small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract
Eligibility:
* Age \>= 18 years
* Histologically confirmed diagnosis of metastatic SCCB or HGNET of the urinary tract
* Participants must have metastatic disease defined as new or progressive lesions.
* Participants must have at least one measurable site of disease
* Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or HGNET of the urinary tract.
Design:
* This is a Phase II, multisite, open label, nonrandomized study with two cohorts.
* All participants will receive lurbinectedin.
* Participants without prior ICI exposure will be eligible to receive concurrent avelumab.
* Treatment will be given in 21-day cycles continuously for up to 10 years or until signs of progression or intolerable side effects.
* Lurbinectedin will be administered intravenously (I.V.) at 3.2mg/m\^2 every 21 days.
* Avelumab will be administered I.V. at 800mg every 21 days.
* The accrual ceiling will be set at 35 to allow for a small number of inevaluable participants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Small Cell Carcinoma of the Bladder
High Grade Neuroendocrine Tumors of the Urinary Tract
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Treatment with lurbinectedin
Group Type
EXPERIMENTAL
Lurbinectedin
Intervention Type
DRUG
Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
Arm 2
Treatment with lurbinectedin and avelumab
Group Type
EXPERIMENTAL
Lurbinectedin
Intervention Type
DRUG
Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
Avelumab
Intervention Type
DRUG
Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lurbinectedin
Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
Intervention Type
DRUG
Avelumab
Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed metastatic small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract (which includes renal pelvis, ureter, and urethra, and excludes neuroendocrine tumors of the prostate). Mixed histologies, with any component including SCCB or HGNETs, are eligible for inclusion.
* Prior treatment as follows:
* For Cohort 1: Participants must have received prior ICIs (PD-1 or PD-L1) or be ineligible for treatment with ICIs.
* For Cohort 2: Participants must be ICI naive but eligible to receive them.
* Participants must have metastatic disease defined as new or progressive lesions.
* Participants must have at least one measurable site of disease, per RECIST 1.1.
* Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or other HGNET of the urinary tract. Platinum ineligibility is defined as a CrCl \<30, or two or more of the following: CrCl \<50-60, ECOG \>=2, hearing loss \>= grade 2, peripheral neuropathy \>= grade 2, New York Heart Association (NYHA) heart failure class \>= class III.
* Age \>=18 years.
* Eastern Cooperative Oncology Group \[ECOG\] performance status (PS) \<=2 (Karnofsky \>=60%).
* Adequate organ and marrow function as defined below:
* Absolute neutrophil count (ANC) \>=1,500/microliter
* Platelets \>=100,000/ microliter
* Hemoglobin (Hgb) \> 9g/dL (erythrocyte transfusions are allowed to achieve acceptable Hgb)
* Total bilirubin within normal limits with the following exceptions:
* Participants with tumor involving the liver may have mild to moderate hepatic impairment with total bilirubin \<= 1.5 x upper limit of normal (ULN)
* Participants with known Gilbert disease who have serum bilirubin level \<= 1.5 x ULN
* Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) \<=1.5 x institutional ULN
---Participants with tumor involving the liver with AST and ALT \<= 5.0 x ULN and bilirubin \<= 1.5 x ULN may be eligible.
* Creatinine clearance (CrCl) \>= 30 mL/min/1.73 m\^2 (glomerular filtration rate \[GFR\] may be used in place of CrCl. Creatinine clearance or eGFR should be calculated per institutional standard)
* Creatine phosphokinase (CPK) \<= 2.5 x ULN
* Participants with previously treated brain metastases or central nervous system (CNS) metastases are eligible if they have recovered from any acute effects of radiotherapy and not requiring steroids, and any whole brain radiation therapy or any stereotactic radiosurgery was completed at least 2 weeks prior to initiation of therapy.
* Human immunodeficiency virus (HIV) positive participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are \> 350 cells/mm\^3 and viral load is undetectable.
* Hepatitis B virus (HBV) positive participants are eligible if they have been treated or are on an appropriate course of antivirals at study entry and with planned monitoring and management according to appropriate guidance including prophylaxis.
* Hepatitis C virus (HCV) positive participants are eligible if:
* they are on active HCV therapy at study entry or are on an appropriate course of antivirals without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling, or if they are post-treatment for HCV; or
* they have a negative polymerase chain reaction (PCR).
* Systemic corticosteroid therapy (defined as \>= the equivalent of prednisone 10 mg/day) or other immunosuppressive agents such as azathioprine or cyclosporin must be discontinued at least 1 week prior to treatment initiation for recent short course use (\<=14 days) or discontinued at least 4 weeks prior to treatment initiation for long term use (\>14 days).
* Contraception requirements as follows:
Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (e.g., intrauterine device \[IUD\], hormonal, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for up to six (6) months after discontinuation of the study drug(s).
* Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to six (6) months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask the partners to be on an effective birth control (hormonal, intrauterine device (IUD), surgical sterilization). Individuals able to father a child must not freeze or donate sperm within the same period.
* Nursing participants must be willing to discontinue nursing from study treatment initiation through six (6) weeks after the last dose of the study drug(s).
* Participants must be able to understand and willing to sign a written informed consent document.
* Prior treatment as follows:
* For Cohort 1: Participants must have received prior ICIs (PD-1 or PD-L1) or be ineligible for treatment with ICIs.
* For Cohort 2: Participants must be ICI naive but eligible to receive them.
* Participants must have metastatic disease defined as new or progressive lesions.
* Participants must have at least one measurable site of disease, per RECIST 1.1.
* Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or other HGNET of the urinary tract. Platinum ineligibility is defined as a CrCl \<30, or two or more of the following: CrCl \<50-60, ECOG \>=2, hearing loss \>= grade 2, peripheral neuropathy \>= grade 2, New York Heart Association (NYHA) heart failure class \>= class III.
* Age \>=18 years.
* Eastern Cooperative Oncology Group \[ECOG\] performance status (PS) \<=2 (Karnofsky \>=60%).
* Adequate organ and marrow function as defined below:
* Absolute neutrophil count (ANC) \>=1,500/microliter
* Platelets \>=100,000/ microliter
* Hemoglobin (Hgb) \> 9g/dL (erythrocyte transfusions are allowed to achieve acceptable Hgb)
* Total bilirubin within normal limits with the following exceptions:
* Participants with tumor involving the liver may have mild to moderate hepatic impairment with total bilirubin \<= 1.5 x upper limit of normal (ULN)
* Participants with known Gilbert disease who have serum bilirubin level \<= 1.5 x ULN
* Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) \<=1.5 x institutional ULN
---Participants with tumor involving the liver with AST and ALT \<= 5.0 x ULN and bilirubin \<= 1.5 x ULN may be eligible.
* Creatinine clearance (CrCl) \>= 30 mL/min/1.73 m\^2 (glomerular filtration rate \[GFR\] may be used in place of CrCl. Creatinine clearance or eGFR should be calculated per institutional standard)
* Creatine phosphokinase (CPK) \<= 2.5 x ULN
* Participants with previously treated brain metastases or central nervous system (CNS) metastases are eligible if they have recovered from any acute effects of radiotherapy and not requiring steroids, and any whole brain radiation therapy or any stereotactic radiosurgery was completed at least 2 weeks prior to initiation of therapy.
* Human immunodeficiency virus (HIV) positive participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are \> 350 cells/mm\^3 and viral load is undetectable.
* Hepatitis B virus (HBV) positive participants are eligible if they have been treated or are on an appropriate course of antivirals at study entry and with planned monitoring and management according to appropriate guidance including prophylaxis.
* Hepatitis C virus (HCV) positive participants are eligible if:
* they are on active HCV therapy at study entry or are on an appropriate course of antivirals without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling, or if they are post-treatment for HCV; or
* they have a negative polymerase chain reaction (PCR).
* Systemic corticosteroid therapy (defined as \>= the equivalent of prednisone 10 mg/day) or other immunosuppressive agents such as azathioprine or cyclosporin must be discontinued at least 1 week prior to treatment initiation for recent short course use (\<=14 days) or discontinued at least 4 weeks prior to treatment initiation for long term use (\>14 days).
* Contraception requirements as follows:
Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (e.g., intrauterine device \[IUD\], hormonal, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for up to six (6) months after discontinuation of the study drug(s).
* Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to six (6) months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask the partners to be on an effective birth control (hormonal, intrauterine device (IUD), surgical sterilization). Individuals able to father a child must not freeze or donate sperm within the same period.
* Nursing participants must be willing to discontinue nursing from study treatment initiation through six (6) weeks after the last dose of the study drug(s).
* Participants must be able to understand and willing to sign a written informed consent document.
Exclusion Criteria
* Prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 14 days prior to the first drug administration. Additionally, FDA-approved hormonal therapy for the treatment or prevention of other malignancies (e.g., breast cancer, prostate cancer) may be continued where in the opinion of the investigator stopping such therapies may increase the risk of disease progression. Potential drug-drug interactions with the hormonal agent will be assessed by the enrolling investigator prior to enrollment.
* Participants previously treated with lurbinectedin.
* History of anaphylactic allergic reactions attributed to compounds of similar chemical or biologic composition to lurbinectedin or avelumab
* Symptomatic or untreated CNS metastases
* For Cohort 2: Active autoimmune disease that might deteriorate when receiving avelumab with the exception of:
* Diabetes type I, eczema, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment
* Requirement of hormone replacement with corticosteroids if the steroids are administered only for the purpose of hormonal replacement and at doses \<= 10mg of prednisone or equivalent per day
* Requirement of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
* Physiologic doses of corticosteroids (\<= the equivalent of prednisone 10 mg/day). The use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to treatment initiation and on study.
* Prior organ transplantation including allogenic stem cell transplantation.
* Participants who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus and locally authorized/approved COVID-19 vaccines are permitted.
* Pregnant people as evaluated by a positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test
* Severe uncontrolled intercurrent illness that would limit compliance with study requirements, evaluated by history, physical exam, and chemistry panel.
* Participants previously treated with lurbinectedin.
* History of anaphylactic allergic reactions attributed to compounds of similar chemical or biologic composition to lurbinectedin or avelumab
* Symptomatic or untreated CNS metastases
* For Cohort 2: Active autoimmune disease that might deteriorate when receiving avelumab with the exception of:
* Diabetes type I, eczema, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment
* Requirement of hormone replacement with corticosteroids if the steroids are administered only for the purpose of hormonal replacement and at doses \<= 10mg of prednisone or equivalent per day
* Requirement of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
* Physiologic doses of corticosteroids (\<= the equivalent of prednisone 10 mg/day). The use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to treatment initiation and on study.
* Prior organ transplantation including allogenic stem cell transplantation.
* Participants who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus and locally authorized/approved COVID-19 vaccines are permitted.
* Pregnant people as evaluated by a positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test
* Severe uncontrolled intercurrent illness that would limit compliance with study requirements, evaluated by history, physical exam, and chemistry panel.
Minimum Eligible Age
18 Years
Maximum Eligible Age
120 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrea B Apolo, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
National Cancer Institute Referral Office
Role: backup
(888) 624-1937
References
Explore related publications, articles, or registry entries linked to this study.
Simon N, Chandran E, Atiq S, Kydd AR, Girardi D, Ley L, Cordes L, Wang TF, Boudjadi S, Stukes I, Smith E, Akbulut D, Niglio S, Patel R, Banday R, Redd B, Gurram S, Steinberg S, Apolo AB. A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale. Future Oncol. 2025 Apr;21(10):1171-1177. doi: 10.1080/14796694.2025.2480534. Epub 2025 Mar 21.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_001523-C.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
001523-C
Identifier Type: -
Identifier Source: secondary_id
10001523
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02845323
ACTIVE_NOT_RECRUITING
PHASE2
Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection
NCT02852564
COMPLETED
PHASE1
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
NCT03617913
COMPLETED
PHASE2
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
NCT06424717
WITHDRAWN
PHASE2
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT01314664
TERMINATED
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
RECRUITING
PHASE1
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
NCT03892642
COMPLETED
PHASE1/PHASE2
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
NCT00749892
COMPLETED
PHASE2
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
NCT02169284
TERMINATED
PHASE2
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
NCT03498196
TERMINATED
PHASE1/PHASE2
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05092958
ACTIVE_NOT_RECRUITING
PHASE3
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
NCT03915405
TERMINATED
PHASE1
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
NCT03519256
TERMINATED
PHASE2
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
NCT02387996
COMPLETED
PHASE2
Suramin in Treating Patients With Recurrent Bladder Cancer
NCT00006476
COMPLETED
PHASE1
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
NCT03258593
COMPLETED
PHASE1
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT04688931
TERMINATED
PHASE3
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
NCT05496192
WITHDRAWN
PHASE2
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
NCT04235764
RECRUITING
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
NCT03601455
ACTIVE_NOT_RECRUITING
PHASE2
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224
RECRUITING
PHASE3
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
NCT02792192
TERMINATED
PHASE1/PHASE2
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
NCT03171025
ACTIVE_NOT_RECRUITING
PHASE2
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
NCT02010203
TERMINATED
PHASE1/PHASE2